Hyloris Pharmaceuticals (XBRU:HYL) EV-to-EBIT : -19.71 (As of Apr. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hyloris Pharmaceuticals's Enterprise Value is €302.86 Mil. Hyloris Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.37 Mil. Therefore, Hyloris Pharmaceuticals's EV-to-EBIT for today is -19.71.

The historical rank and industry rank for Hyloris Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

XBRU:HYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -51.19 Med: -31.91 Max: -18.34
Current: -19.71

During the past 8 years, the highest EV-to-EBIT of Hyloris Pharmaceuticals was -18.34. The lowest was -51.19. And the median was -31.91.

XBRU:HYL's EV-to-EBIT is ranked worse than
100% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs XBRU:HYL: -19.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hyloris Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was €328.06 Mil. Hyloris Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.37 Mil. Hyloris Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.68%.

Hyloris Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Hyloris Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EV-to-EBIT Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-30.79

-40.47

-26.72

-21.35

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial							-40.47	-	-26.72	-	-21.35

Competitive Comparison of Hyloris Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Hyloris Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's EV-to-EBIT falls into.

Hyloris Pharmaceuticals EV-to-EBIT Calculation

Hyloris Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	302.860	/	-15.369
	=	-19.71

Hyloris Pharmaceuticals's current Enterprise Value is €302.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.37 Mil.

Hyloris Pharmaceuticals (XBRU:HYL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hyloris Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-15.369	/	328.0611
	=	-4.68 %

Hyloris Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was €328.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-15.37 Mil.

Hyloris Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.